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Objectives
The aim of the present study was to assess the effects of nutritional supplementation
on neuropsychiatric symptoms among people with dementia.
Methods/Design: Randomized controlled trials (RCTs) were searched in the Data-
bases PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials
and Clinicaltrials.gov from inception until January 31, 2020. Studies of RCTs carried
out on people with any type of dementia who were taking nutritional supplements
and had neuropsychiatric symptoms were included in this systematic review and
meta-analysis. Neuropsychiatric symptoms were assessed with the validated Neuro-
psychiatric Inventory (NPI). Effect sizes were calculated with standardized mean dif-
ferences (SMD) and 95% confidence intervals (95%CI), applying a random effect
model.
Results: The search yielded 1034 studies with four studies being included in the
meta-analysis with a total of 377 people with dementia (mean age 69.3 [SD: 7.7]
years). The diagnoses comprised mild to late Alzheimer's disease and frontotemporal
dementia. Two studies included a multicomponent supplementation, one an
omega-3, and one a special supplement tailored for cognitive impairment. The
median follow-up was 18 weeks, with a range from 12 to 24 weeks. Pooled data
showed that nutritional supplementation did not improve NPI (SMD = −0.33; [95%
CI: −0.74 to 0.08]; P = 0.11; I2 = 45%).
Conclusions: The findings of this meta-analysis demonstrated no significant impact
on NPI through nutritional supplementation. However, the generalization of the
results is limited, as different supplements were used in different stages of dementia
with a short follow-up time.
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1 | INTRODUCTION
Dementia is a clinical syndrome characterized by neurodegeneration
and cognitive decline with a progressive deterioration of depen-
dence.1 It was estimated that 50 million people lived with dementia
worldwide in 2019, with 10 million new cases every year, and this is
projected to triple by 2050.2 As the global population ages, not only
dementia but also dementia-related problems increase the burden to
families, caregivers and healthcare systems.3
People with dementia may experience serious adverse events
(eg, falls, fractures, postural hypotension, metabolic syndrome, car-
diac arrhythmia, sedation and cognitive decline),4 leading to long-
term hospitalization, decreased quality of life for caregivers and
patients and increased mortality.5 Additionally, behavioral and psy-
chological symptoms in dementia (BPSD) are among the most com-
mon causes of this burden and often occur as a result of
deterioration in mood, thought, perception and behavior.6,7 Although
several studies have highlighted the role of genetic, neurochemical
and neuropathological factors,8-14 the underlying pathogenesis of
BPSD in detail is not yet clear.
BPSD affect nearly all people with dementia,15 and are prevalent
in the mild stages of dementia, increasing within the progression of
the neurodegenerative process.16 One recent study demonstrated
that the prevalence of a single BPSD was 74% among people with
mild cognitive impairment (MCI), and 85% among people with mild to
moderate dementia, respectively.17 Considering these high propor-
tions, it is clear that the prevention and treatment of BPSD is of
upmost importance. Pharmacological therapies are used to reduce the
frequency and severity of BPSD, when non-pharmacological interven-
tions are ineffective.18 However, they provide only moderate symp-
tom control.18 Therefore, new interventions are considered a
preferable alternative.
Nearly half of elderly people with dementia have a risk of mal-
nutrition which also increases cognitive impairments and the
incidence of behavioral disorders.19,20 Therefore, nutritional supple-
ments are thought to have an effect on BPSD. Concerning supple-
mentation, the World Health Organization (WHO) does not
recommend multi-complex supplements, Vitamin B, C or E or poly-
unsaturated fatty acids to reduce the risk of cognitive decline.2 Addi-
tionally, the results of a Cochrane Review showed that the effects of
vitamins (E, C, B) and mineral supplements as treatments for MCI are
very limited.21
However, the effectiveness and improvements toward BPSD
remain unclear.22 Therefore, the aim of the present study was to con-
duct a systematic review and meta-analysis of randomized controlled
trials (RCTs) to determine whether nutritional supplementations have
an effect on BPSD in people with dementia.
2 | METHODS
This systematic review adhered to the PRISMA statement23 and
followed a pre-planned, but unpublished protocol.
2.1 | Data sources and literature search strategy
Two investigators (SS and AS) independently conducted a literature
search using PubMed, EMBASE, SCOPUS, Cochrane Central Register
of Controlled Trials and Clinicaltrials.gov without language restriction,
from database inception until January 31, 2020 for RCTs, investigat-
ing the effect of nutritional supplementations in the treatment of NPIs
in people affected by dementia. Any inconsistencies were resolved by
consensus with a third author (SH).
In PubMed, the following search strategy was used: “(supple-
ment*) AND (Alzheimer OR dementia) and (neuropsych*).” An adapted
search was conducted in other databases. Conference abstracts and
reference lists of included articles were hand-searched to identify any
other potentially relevant articles.
2.2 | Study selection
Inclusion criteria for this meta-analysis were: (a) RCTs, (b) people
with any type of dementia; (c) at least one group treated with a
nutritional supplement; and (d) using neuropsychiatric symptoms (eg,
Neuropsychiatric Inventory = NPI)24 as validated outcomes. For
neuropsychiatric symptoms, we intended the onset of delusions,
hallucinations, agitation/aggression, dysphoria, anxiety, euphoria,
apathy, disinhibition, irritability/lability, aberrant motor activity,
night-time behavioral disturbances and appetite and eating abnor-
malities.24 For nutritional supplementations, we intended nutrients
(or a combination of nutrients) that may otherwise not be consumed
in sufficient quantities.
2.3 | Data extraction
The data were extracted from the included articles in a standardized
Excel sheet, and checked by an independent investigator. For each
article, we extracted data concerning the authors, year of publication,
country, type of dementia, setting, type of nutritional intervention,
number of participants and their mean age and standard deviation
(SD) and duration of follow-up (in weeks). Additionally, the percentage
of women with dementia was extracted.
Key points
• Pooled effects of this meta-analysis showed no effects of
nutritional supplements on behavioral and psychological
symptoms in people with dementia.
• However, results showed high heterogeneity among the
studies in terms of sample characteristics as well as the
investigated supplements.
• Consequently, more research is needed.
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2.4 | Outcomes
The primary outcome was the changes in NPI between baseline and
follow-up in people treated with a nutritional supplementation vs placebo.
2.5 | Assessment of study quality
The quality of the included studies was assessed using the Jadad's scale.25
This scale quantifies the trial quality based on the description and appro-
priateness of randomization (2 points), blinding procedures (2 points) and
description of withdrawals (1 point). A value less than 3 (over a maximum
of 5) usually indicates a low-quality study at high risk of bias.25
2.6 | Data synthesis and statistical analysis
All analyses were performed using Comprehensive Meta-Analysis
(CMA) Version 3. When multiple assessments were made, the longest
follow-up time was included in the analyses. The primary analysis com-
pared the values of NPI between people with dementia treated with
nutritional supplementation vs placebo. We calculated the difference
between the means of the treatment and control groups using the
follow-up data through standardized mean differences (SMD) with
their 95% confidence intervals (CIs), applying a random-effect model.26
Heterogeneity across studies was assessed by the I2 metric. Given
significant heterogeneity (I2 ≥ 50%, P < 0.05) and for outcomes having
at least four studies, we planned to run a meta-regression analysis tak-
ing as moderators mean age, baseline values of NPI, setting, type of
dementia, the follow-up duration of the RCTs included.
Publication bias was assessed by a visual inspection of funnel
plots and calculating the Egger bias test.27 Then, to account for
publication bias, the trim-and-fill method was used,28 based on the
assumption that the effect sizes of all the studies are normally dis-
tributed around the center of a funnel plot; in the event of
asymmetries, the test adjusts for the potential effect of unpublished
studies.28 Finally, the fail-safe number (ie, the number of missing
studies that would bring P-value over the alpha) was considered.28
For all analyses, a P-value less than 0.05 was considered statistically
significant.
3 | RESULTS
3.1 | Search results
Altogether, the searches yielded 1034 records. After excluding
1018 articles based on title/abstract review, 12 articles were
retrieved for full text review and four RCTs29-32 were finally
included (Figure 1).
F IGURE 1 PRISMA flow-
chart [Colour figure can be
viewed at wileyonlinelibrary.com]
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3.2 | Study and participant characteristics
Full descriptive details of the included studies are reported in Tables 1
and Supplementary Table 1. All the studies included a total of
377 people with dementia, with a mean age of 69.3 (SD: 7.7) years.
All except one31 included people having a diagnosis of Alzheimer's dis-
ease, and all except one29 were carried out on community-dwelling
people. The type of nutritional intervention is fully reported in the
Table 1. Two studies29,30 included a multicomponent nutritional sup-
plement, one included an omega-3 supplement,32 and one31 a supple-
ment tailored for cognitive impairment. The median follow-up was
18 weeks, with a range from 12 to 24 weeks. In all studies, the NPI
was used for assessing the association between nutritional supple-
mentations and neuropsychiatric symptoms. All the studies have a
sufficient quality, as indicated by the Jadad's score (Table 1).
Supplementary Table 1 shows sample characteristics in the
included studies. The 204 people with dementia randomized to the
nutritional supplementation group did not differ in mean age (69.0
[SD: 8.1] vs 69.7 [SD: 9.0] years, P = 0.84), mini-mental state examina-
tion (22.9 [SD: 3.4] vs 22.7 [SD: 3.9] points, P = 0.78), or NPI (16.0
[SD: 2.2] vs 15.0 [SD: 2.2] points, P = 0.95) at baseline
(Supplementary Table 1).
3.3 | Effect of nutritional supplementations on
neuropsychiatric symptoms
All four studies29-32 indicated that the use of nutritional supplements
did not improve neuropsychiatric symptoms (SMD = −0.33 [95%CI:
−0.74 to 0.08]; P = 0.11; I2 = 45%) (Figure 2). No evidence of a publi-
cation bias emerged (Egger's test = −2.46 [1.78]; P = 0.30), even if the
trim and fill analysis further attenuated the effect of nutritional sup-
plementations (adjusted SMD = −0.08 [95%CI: −0.53 to 0.38]). The
fail-safe number was four.
In one RCT with data not meta-analyzable (NPI was given in
categories),33 the use of supplement tailored for cognitive impairment
did not improve neuropsychiatric symptoms (P = 0.73).
3.4 | Adverse events
No severe adverse events were reported in any study, and the inci-
dence of adverse events was similar in both groups (OR = 1.10 [95%
CI: 0.31-3.88] P = 0.88), being gastrointestinal symptoms the most
common. Three studies reported data regarding side effects.29-31
4 | DISCUSSION
A total of four RCTs were included in the present meta-analysis,
whereas two of those studies29,30 were carried out with a mul-
ticomponent nutritional supplement, one with an omega-3,32 and
one31 with a supplementation tailored for cognitive impairment. The
results indicate non-significant improvement in NPI by nutritional sup-
plementation in this group.
Nonetheless, since people with dementia are at higher risk of mal-
nutrition, mainly caused by a declined ability to feed themselves,34
and pharmacotherapy reduce eating drive,35,36 nutritional
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supplements might be helpful to prevent malnutrition, when nutri-
tional goals cannot be met through dietary counselling.37 Additionally,
many of the nutrients are essential for brain tissue, as they are precur-
sors of neurotransmitters, or have important functions in the meta-
bolic process.38 However, the present evidence does not support the
use of supplements. Indeed, previous literature has suggested that
supplements are unlikely to prevent cognitive decline in people with
dementia.2,21,39 In line with these guidelines, the results of the present
meta-analysis also suggest that supplements need not be rec-
ommended to people with dementia, as we did not find any significant
effect on NPI. However, when interpreting the results, the following
facts should be kept in mind.
The included studies used completely different supplements.
Therefore, making a general statement on the effects of supplements
on BPSDs is difficult. Two out of four studies used a multicomponent
nutritional supplement (folic acid, vitamin B12, vitamin E, S-adenosyl
methionine, N-acetyl cysteine, acetyl-L-carnitine).29,30
One of these studies showed improvements in NPI with no statis-
tical difference to the placebo group within 3 months,29 whereas peo-
ple with dementia in another study using the same supplements
reported no changes in NPI, neither in the supplementation nor in the
placebo group.30 Additionally, although some studies have shown that
omega-3 supplements may have a protective effect on neuropsychiat-
ric diseases, as they modulate the release of important transmitters
(acetylcholine, serotonin and dopamine),40 the included study of
Freund-Levi was not able to show any effect on NPI after 6 months.32
The only study demonstrating a significant improvement in NPI was
published by Pardini et al.31 In this examination, Souvenaid, a tailored
supplement for dementia, that showed to influence the ability in
improving synaptic integrity, was given.31 Notably, in this examination,
younger people with frontotemporal dementia were included and had
higher baseline NPI scores (supplementation: 24.0 [0.7]; placebo: 23.0
[0.6]) compared to Freund-Levi et al32 (supplementation: 15.6
[12.9-18.2]; placebo: 14.9 [12.1-17.7]) and Remington et al30 (supple-
mentation: 11.5 [9.1]; placebo 10.8 [12.4]).
Consequently, as can be taken from these baseline NPIs,
another reason for the non-effect could probably be that the NPI
values were too low to see any effect in a rather short time. This,
the so-called floor effect, makes it difficult for various tests to per-
form well.41
Another reason could be the differences in the study samples in
the included studies. One study investigated people with mild to mod-
erate AD,32 another included people with moderate to late-stage
AD,29 the other younger people with frontotemporal dementia,31 and
in one study the dementia staging was omitted.30 Since BPSDs start
already from mild stages of dementia and increase with the
progression,16 nutritional interventions preventing BPSD might be
interesting in early stage. Additionally, the fact that in the study of
Remington et al,30 supplementation was more effective in people at
earlier stages of AD, and it strengthens the importance of early inter-
ventions. Notably, in this case, only small treatment effects might be
detected, making a long follow up time necessary.
This literature review presents different limitations. Due to a
small number of studies in people with dementia, we could only
include four studies. Further, as mentioned above, the supplements
differ among the studies, lowering the strength of the conclusions of
the meta-analysis. Additionally, the follow up time may have been too
short to see effects on BPSD.
5 | CONCLUSIONS AND IMPLICATIONS
Taken together, the findings of this meta-analysis demonstrate no sig-
nificant impact of various nutritional supplements in people with
dementia on BPSD assessed by NPI. The generalization of the results
is limited, as different supplements were used in different stages of
dementia with a rather short follow-up time. Nevertheless, the neces-
sity of nutritional supplementation might be given in order to prevent
malnutrition. Consequently, more studies with the same supplements
(eg, vitamin B, polyunsaturated fatty acids) are recommended in
F IGURE 2 Effect of nutritional supplementations on neuropsychiatric symptoms. Used supplements: omega-3 (430 mg DHA and 150 mg
EPA)1; Souvenaid2; multicomponent supplement: (400 μg folic acid, 6 μg B12, 30 I.U. 88 alpha-tocopherol, 400 mg SAM [200 mg active ion],
600 mg NAC, 500 mg ALCAR)3; multicomponent supplement (400 μg folic acid, 6 μg B12, 30 I.U. 88 alpha-tocopherol, 400 mg SAM [200 mg
active ion], 600 mg NAC, 500 mg ALCAR).4 CI, confidence intervals; IV, inverse variance; SD, standard deviations
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earlier stages of dementia with a longer follow up time to provide
more definitive answers, regarding the effectiveness of nutritional
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